Advanced diagnostic and prognostic solutions for urological cancer care 

No matter which test(s) you receive from our growing portfolio of traditional and breakthrough products and services, rest assured they are backed by our superior clinical expertise and the
highest level of customer support.

Press Release

Metamark Receives Positive Medicare Final Coverage Decision for ProMark

Metamark Genetics, Inc. today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses novel molecular diagnostic technologies, has issued final local coverage determination (LCD) for ProMarkĀ®, the first and only proteomic prognostic test for early-stage prostate cancer.

read article
Press Release

Metamark Announces Agreement with Blue Cross and Blue Shield of Texas

Metamark Genetics, Inc., a leader in providing critical diagnostic and prognostic information to enable more informed treatment decisions for urological cancer, today announced that effective June 1, 2016, the Company signed an agreement with Blue Cross and Blue Shield of Texas (BCBSTX).

read article
Displaying results 1-2 (of 13)
 |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7  >  >|